EGFR and non-small cell lung carcinoma: Mutations in the epidermal growth factor receptor (EGFR) gene and rearrangements of the anaplastic lymphoma kinase (ALK) gene are markers for determining the appropriate treatment for advanced NSCLC [4] and have now passed into routine clinical use as predictive biomarkers.